232 related articles for article (PubMed ID: 9427717)
1. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Sterkers Y; Preudhomme C; Laï JL; Demory JL; Caulier MT; Wattel E; Bordessoule D; Bauters F; Fenaux P
Blood; 1998 Jan; 91(2):616-22. PubMed ID: 9427717
[TBL] [Abstract][Full Text] [Related]
2. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases.
Merlat A; Lai JL; Sterkers Y; Demory JL; Bauters F; Preudhomme C; Fenaux P
Leukemia; 1999 Feb; 13(2):250-7. PubMed ID: 10025899
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
[TBL] [Abstract][Full Text] [Related]
4. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ.
Soenen V; Preudhomme C; Roumier C; Daudignon A; Laï JL; Fenaux P
Blood; 1998 Feb; 91(3):1008-15. PubMed ID: 9446663
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Brusamolino E; Passamonti F; Volpe G; Pistorio A; Giardini I; Rocca B; Caresana M; Lazzarino M; Bernasconi C
Leukemia; 2002 Oct; 16(10):2078-83. PubMed ID: 12357360
[TBL] [Abstract][Full Text] [Related]
6. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
7. Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
Randi ML; Fabris F; Girolami A
Leuk Lymphoma; 2000 Apr; 37(3-4):379-85. PubMed ID: 10752989
[TBL] [Abstract][Full Text] [Related]
8. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature.
Liozon E; Brigaudeau C; Trimoreau F; Desangles F; Fermeaux V; Praloran V; Bordessoule D
Hematol Cell Ther; 1997 Feb; 39(1):11-8. PubMed ID: 9088933
[TBL] [Abstract][Full Text] [Related]
9. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
10. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
[TBL] [Abstract][Full Text] [Related]
11. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
[TBL] [Abstract][Full Text] [Related]
12. Is hydroxyurea leukemogenic in essential thrombocythemia?
Tefferi A
Blood; 1998 Aug; 92(4):1459-60; author reply 1460-1. PubMed ID: 9694740
[No Abstract] [Full Text] [Related]
13. Translocations (5;17) and (7;17) in patients with de novo or therapy-related myelodysplastic syndromes or acute nonlymphocytic leukemia. A possible association with acquired pseudo-Pelger-Huët anomaly and small vacuolated granulocytes.
Laï JL; Zandecki M; Fenaux P; Le Baron F; Bauters F; Cosson A; Deminatti M
Cancer Genet Cytogenet; 1990 Jun; 46(2):173-83. PubMed ID: 2340488
[TBL] [Abstract][Full Text] [Related]
14. Cytogenetic analysis of de novo acute myeloid leukemia with trilineage myelodysplasia in comparison with myelodysplastic syndrome evolving to acute myeloid leukemia.
Tamura S; Takemoto Y; Hashimoto-Tamaoki T; Mimura K; Sugahara Y; Senoh J; Furuyama JI; Kakishita E
Int J Oncol; 1998 Jun; 12(6):1259-62. PubMed ID: 9592183
[TBL] [Abstract][Full Text] [Related]
15. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms.
Björkholm M; Derolf AR; Hultcrantz M; Kristinsson SY; Ekstrand C; Goldin LR; Andreasson B; Birgegård G; Linder O; Malm C; Markevärn B; Nilsson L; Samuelsson J; Granath F; Landgren O
J Clin Oncol; 2011 Jun; 29(17):2410-5. PubMed ID: 21537037
[TBL] [Abstract][Full Text] [Related]
16. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
[TBL] [Abstract][Full Text] [Related]
17. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
18. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
19. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
[TBL] [Abstract][Full Text] [Related]
20. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
Christiansen DH; Andersen MK; Pedersen-Bjergaard J
J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
